Compare BNBX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNBX | XBIO |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.9M |
| IPO Year | N/A | N/A |
| Metric | BNBX | XBIO |
|---|---|---|
| Price | $1.62 | $2.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 267.8K | 32.0K |
| Earning Date | 02-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,136,935.00 | ★ $2,858,935.00 |
| Revenue This Year | $253.12 | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.11 | ★ 13.30 |
| 52 Week Low | $1.16 | $1.90 |
| 52 Week High | $183.75 | $13.93 |
| Indicator | BNBX | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.21 |
| Support Level | N/A | $2.10 |
| Resistance Level | N/A | $2.25 |
| Average True Range (ATR) | 0.00 | 0.11 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 71.15 |
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.